ROG | Jotup

FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer

Retrieved on:

목요일, 4월 18, 2024

Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumor.

Key Points:

Alecensa is now the first and only ALK inhibitor approved for people with ALK-positive early-stage NSCLC who have undergone surgery to remove their tumor.
“At Genentech, our goal is to give patients the best chance of cure by bringing effective, targeted treatments to early-stage disease before their cancer has spread.
In an exploratory analysis, an improvement of central nervous system (CNS)-disease-free survival (DFS) was observed (HR=0.22; 95% CI: 0.08-0.58).
Alecensa is a kinase inhibitor currently approved as first- and second-line treatment for ALK-positive metastatic NSCLC.

Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS

Retrieved on:

수요일, 4월 17, 2024

Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation.

Key Points:

Results showed near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential benefits of this investigational formulation.
“Updated results from OCARINA II further underline the potential benefits of subcutaneous Ocrevus for patients with both relapsing and progressive forms of MS,” said Scott Newsome, D.O., lead author, Johns Hopkins University School of Medicine.
“Patients treated with subcutaneous Ocrevus experienced appropriate B-cell suppression and impressive near-complete suppression of new inflammatory disease activity.
There are more than 30 ongoing Ocrevus clinical trials designed to help us better understand MS and its progression.

Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study

Retrieved on:

월요일, 4월 15, 2024

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall survival.

Key Points:

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall survival.
Safety of the combination appeared consistent with the known safety profiles of the individual medicines.
The data will be submitted to health authorities and shared at an upcoming medical meeting.
Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to be off-the-shelf and ready for infusion, so patients can start treatment soon after diagnosis.

Rogers Schedules First Quarter 2024 Earnings Call for April 25

Retrieved on:

목요일, 4월 11, 2024

Alternative Energy, EV, Electric Vehicles, Energy, Automotive, Engineering, Technology, Manufacturing, Other Technology, ROG, Senior, Rogers Corporation

Rogers Corporation (NYSE:ROG) (“Rogers”) plans to announce first quarter 2024 results on April 25, 2024 after market close, which will be followed by a conference call at 5:00 pm ET.

Key Points:

Rogers Corporation (NYSE:ROG) (“Rogers”) plans to announce first quarter 2024 results on April 25, 2024 after market close, which will be followed by a conference call at 5:00 pm ET.
The call will be hosted by Colin Gouveia, President and Chief Executive Officer, who will be joined by Ram Mayampurath, Senior Vice President and Chief Financial Officer.
A live webcast of the event and related slide presentation can be accessed on Rogers’ Investor Relations website at https://rogerscorp.com/investors .
A replay of the event will also be available on the Investor Relations’ website.

Air Products Announces Plans to Build Network of Commercial-Scale Multi-Modal Hydrogen Refueling Stations Connecting Edmonton and Calgary, Alberta, Canada

Retrieved on:

화요일, 4월 23, 2024

LEHIGH VALLEY, Pa., April 23, 2024 /PRNewswire/ -- Air Products (NYSE:APD) today announced it intends to build a network of permanent, commercial-scale multi-modal hydrogen refueling stations stretching from Edmonton to Calgary, Alberta, Canada.

Key Points:

LEHIGH VALLEY, Pa., April 23, 2024 /PRNewswire/ -- Air Products (NYSE:APD) today announced it intends to build a network of permanent, commercial-scale multi-modal hydrogen refueling stations stretching from Edmonton to Calgary, Alberta, Canada.
"Last year, Air Products announced our continued investment in Western Canada with the first permanent, commercial-scale hydrogen refueling station in Alberta.
Today, we build on that commitment with plans to build additional commercial-scale multi-modal hydrogen refueling stations, developing a hydrogen highway connecting Alberta's two largest cities and enabling the continued development of the region's hydrogen ecosystem."
The first of Air Products' permanent hydrogen refueling stations, located in Edmonton, near the site of the Company's landmark net-zero hydrogen energy complex that is under construction, is scheduled to be onstream in 2025.

Air Products' Chairman, President and Chief Executive Officer Seifi Ghasemi to Deliver Keynote Address at the Canadian Hydrogen Convention

Retrieved on:

화요일, 4월 16, 2024

Hydrogen, Air Products, Natural gas, ROG, Alberta's Industrial Heartland, Imperial, Transport, Edmonton Convention Centre, Carbon, Convention, Convention center

LEHIGH VALLEY, Pa., April 16, 2024 /PRNewswire/ -- Air Products' (NYSE:APD) Chairman, President and Chief Executive Officer Seifi Ghasemi will deliver the keynote address at the 2024 Canadian Hydrogen Convention at 9:45 a.m. MT/11:45 a.m. ET on Tuesday, April 23, 2024 at the Edmonton Convention Centre in Edmonton, Alberta, Canada.

Key Points:

LEHIGH VALLEY, Pa., April 16, 2024 /PRNewswire/ -- Air Products' (NYSE:APD) Chairman, President and Chief Executive Officer Seifi Ghasemi will deliver the keynote address at the 2024 Canadian Hydrogen Convention at 9:45 a.m. MT/11:45 a.m.
"Clean hydrogen is key to decarbonizing hard-to-abate industrial and heavy-duty transportation sectors of the economy and to meeting climate goals," said Ghasemi.
Air Products Canada currently operates three hydrogen production facilities in Alberta, and a 55-kilometer hydrogen pipeline in the Alberta Industrial Heartland.
In addition, Air Products is building the first commercial-scale multi-modal hydrogen refueling station in Edmonton―located near Air Products' net-zero hydrogen energy complex―to serve heavy-duty and light-duty vehicles.

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

Retrieved on:

수요일, 4월 10, 2024

Breast cancer, FDA, Patient, Cancer, Daiichi Sankyo, Lung cancer, HER2, Food, ROG, Marie Cassidy, ADC, Food and Drug Administration, AstraZeneca, CE marking, Medical imaging

ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca.

Key Points:

ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca.
To determine a patient's HER2 status, pathologists evaluate, or score, the level of HER2 protein expressed in breast cancer tissue samples.
However, half of all patients with metastatic breast cancer express low levels of HER2 which historically classified them as HER2-negative.
Breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases diagnosed worldwide each year.

Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU

Retrieved on:

수요일, 4월 10, 2024

Breast cancer, FDA, Patient, Cancer, Daiichi Sankyo, Lung cancer, HER2, Food, ROG, Marie Cassidy, ADC, Food and Drug Administration, AstraZeneca, CE marking, Medical imaging

ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca.

Key Points:

ENHERTU is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialised by Daiichi Sankyo and AstraZeneca.
To determine a patient's HER2 status, pathologists evaluate, or score, the level of HER2 protein expressed in breast cancer tissue samples.
However, half of all patients with metastatic breast cancer express low levels of HER2 which historically classified them as HER2-negative.
Breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases diagnosed worldwide each year.

Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024

Retrieved on:

화요일, 3월 12, 2024

Diagnosis, Conference, Digital, Health, Health care, AI, Laboratory, HIMSS, POC, ROG, Pathology

navify Analytics for POC will make its debut at the HIMSS 2024 Conference in Orlando, USA, from 11-15 March 2024.

Key Points:

navify Analytics for POC will make its debut at the HIMSS 2024 Conference in Orlando, USA, from 11-15 March 2024.
"Digital advances, such as AI, are transforming healthcare, and we have exciting new opportunities to increase the speed of diagnosis and improve outcomes for patients," said Moritz Hartmann, Global Head of Roche Information Solutions at Roche Diagnostics.
At HIMSS (Roche Booth#2911), Roche will present its full array of navify digital solutions, an integrated and secure set of solutions that delivers connectivity and data-driven insights to enhance efficiency and interoperability in healthcare.
Roche and external speakers will also discuss the impact of digital transformation in healthcare from screening, diagnosis, to personalised care including:

Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024

Retrieved on:

화요일, 3월 12, 2024

Diagnosis, Conference, Digital, Health, Health care, AI, Laboratory, HIMSS, POC, ROG, Pathology

navify Analytics for POC will make its debut at the HIMSS 2024 Conference in Orlando, USA, from 11-15 March 2024.

Key Points:

navify Analytics for POC will make its debut at the HIMSS 2024 Conference in Orlando, USA, from 11-15 March 2024.
"Digital advances, such as AI, are transforming healthcare, and we have exciting new opportunities to increase the speed of diagnosis and improve outcomes for patients," said Moritz Hartmann, Global Head of Roche Information Solutions at Roche Diagnostics.
At HIMSS (Roche Booth#2911), Roche will present its full array of navify digital solutions, an integrated and secure set of solutions that delivers connectivity and data-driven insights to enhance efficiency and interoperability in healthcare.
Roche and external speakers will also discuss the impact of digital transformation in healthcare from screening, diagnosis, to personalised care including: